Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Metformin; Pioglitazone; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CANTATA-MP
- Sponsors Janssen Research & Development
- 18 Mar 2019 Time matched evaluation of cardiovascular risk associated with drugs using 10 trials (EXAMINE, SAVOR TIMI 53, TECOS, ELIXA, LEADEER, SUSTAIN-6, EXSCEL, EMPA-REG OUTCOME, CANVAS Program and DECLARE-TIMI 58); results published in the Clinical Drug Investigation
- 15 Sep 2017 Results of a post-hoc analysis assessing the effect of Canagliflozin on liver function tests and liver fibrosis in patients from four phase III trials (CANTATA-M, CANTATA-MSU, CANTATA-D and CANTATA-MP) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 01 Apr 2017 Pooled results of a post hoc analysis assessing the effects of canagliflozin on serum magnesium in hypomagnesemic patients from four placebo-controlled studies (CANTATA-MP, CANTATA-M, CANTATA-MSU, and CANTATA-D; n=2313) published in the Diabetes Therapy